
    
      This is a phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating
      the efficacy and safety of ustekinumab in the treatment of participants with active
      non-radiographic axial spondylo arthritis. Participants will receive either placebo or
      ustekinumab 45 or 90 milligram (mg). Participants will primarily be assessed for Assessment
      of Spondylo Arthritis (ASAS) International Society criteria 20 at Week 24. Safety will be
      monitored throughout the study.
    
  